Payer use of ICER reports

The Academy of Managed Care Pharmacy (AMCP) held an interesting webinar titled “5 Years of ICER – Insights and Impact on Payers“. Some highlights form the presentation. Most relevant information Jeremy Lee from MedImpact–a pharmacy benefits manager (PBM)–noted that their Pharmacy and Therapeutics (P&T) committee used four key pieces of evidence when making coverage and…

Does the government really need to provide financial support for COVID vaccine development?

Based on an a medRχiv working paper by Vu by et al. (2020), the answer from an analysis of other emerging infectious diseases (EIDs) is an overwhelming ‘yes’. The authors analyze hypothetical investment returns of a portfolio of 141 pre-clinical emerging infectious disease (EID) vaccine development programs across different emerging infections without a vaccine. These…

Treatment effect heterogeneity, self-selection into RCTs, and racial disparities

In drug development, clinical trials typically aim for a population that is representative of the patients who would be eligible for the treatment. While randomized controlled trials (RCTs) typically focus on measuring the average health impact of a drug across this population, a paper Basu and Gurjal (2020) argue that treatment effect heterogeneity and self-selection…

$1 billion antibiotic venture fund launched

Antibiotic resistance is a problem. One study from Europe found that in 2015 there were 33,110 deaths attributable to antibiotic resistance; accounting for morbidity as well, antibiotic resistance lead to a a decrease of 874,541 disability-adjusted life years. CDC data show that antibiotic resistant bacteria and fungi caused 35,900 deaths in 2019, 12,800 deaths due…

The slow uptake of biosimilars in the US

From Cahan, Kocher, and Bohn in the Health Affairs blog: Since passage of the 2010 “Biosimilars” Act aimed at stimulating non-inferior innovation and competition in therapeutics markets, only 17 agents have been approved, and only seven have made it to market. Why haven’t biosimilars been more attractive? Blackstone et al. (2013) cites 3 key issues:…